Prospective Comparison of SGLT-2 inhibitor, Luseogliflozin,versus GLP-1 Receptor Agonist,Dulaglutide, on Regression of Coronary Atherosclerosis with Type 2 Diabetes Mellitus who have Undergone Percutaneous Coronary Intervention: Open-label Randomized Parallel-group Trial

Prospective Comparison of SGLT-2 inhibitor, Luseogliflozin,versus GLP-1 Receptor Agonist,Dulaglutide, on Regression of Coronary Atherosclerosis with Type 2 Diabetes Mellitus who have Undergone Percutaneous Coronary Intervention: Open-label Randomized Parallel-group Trial - STILL-GLORY trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026630

Enrollment

200

Registered

2017-04-01

Start date

2017-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes who have undergone percutaneous coronary intervention

Interventions

patients recieving SGLT-2 inhibitor, luseogliflozin 2.5-5 mg/day, for 12 months patients recieving GLP-1 receptor agonist, dulaglutide 0.75mg/week, for 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes who have undergone percutaneous Coronary intervention 2. Type 2 diabetes do not have poor glycemic control (HbA1c>7.0%), 3. Type 2 diabetes not recieving GLP-1 RA and SGLT-2 inhibitor before this trial, at least 3 months

Exclusion criteria

Exclusion criteria: Exclusion criteria were (1) type 1 diabetes, (2) severe complications of diabetes (3) hypersensitivity to the components of dulaglutide or luseogliflozin (4) severe liver, renal dysfunction (5) severe heart failure (NYHA 3,4) (6) pregnant or nursing women and those who might be pregnant (7) Familial Hypercholesterolemia: FH (8) Treatment with PCSK-9 inhibitor (9) any patients whom the investigators judgd to be inappropriate for this study.

Design outcomes

Primary

Measure	Time frame
Change in percent atheroma volume for 12 months during the treatment from baseline to study completion.	—

Countries

Japan

Contacts

Public ContactTeruo Jojima

Dokkyo medical university hospital Endocrinology and Metabolism

jojima@dokkyomed.ac.jp0282-86-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026